市場調查報告書
商品編碼
1532127
臨床試驗成像的全球市場的評估:各類服務,各種模式,各治療領域,各終端用戶,各地區,機會,預測(2017年~2031年)Clinical Trial Imaging Market Assessment, By Services, By Modality, By Therapeutic Area, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球臨床試驗影像市場規模預計將從 2023 年的 13.5 億美元增至 2031 年的 25 億美元,預計 2024-2031 年的複合年增長率為 8.01%。該市場受到研發費用增加、醫學影像公司擴張以及臨床研究組織(CRO)數量增加等因素的推動。
醫學影像對於先進生命科學設備和套件的開發至關重要。儘管醫學影像市場不斷變化,但生物技術和製藥行業卻表現出持續成長。這主要是由於對醫學影像公司的投資和併購增加,包括採用創新影像技術來促進醫療設備的臨床試驗。技術進步極大地改善了臨床試驗影像資料的收集、解釋和提交。基於技術的成像,尤其是影像分析軟體,為臨床研究提供了多種好處,包括均勻性、資料品質、靈活性和合規性。例如,影像分析軟體可以透過評估拍攝影像的時間點來指導和監督閱片醫師。此外,隨著處理能力的提高,成像技術的使用也在增加,並且在臨床試驗中的影像使用預計將加速。定量成像生物標記聯盟 (QIBA) 計畫開發了標準化方法和成像流程,以在臨床試驗中實現科學且精確定義的結果。
2024 年5 月,Parexel International Corporation(Calyx Medical Imaging)宣布啟動Iovance Biotherapeutic 的Amtagvi (lifileucel) 的關鍵II 期臨床試驗,這是一種針對現有一線治療失敗的轉移性黑色素瘤患者的細胞療法。 Calyx 支持臨床試驗的診斷影像部分的開發和實施。因此,60個研究中心能夠根據影像評估方法收集患者的CT、磁振造影(MRI)、正子斷層掃描(PET)和皮膚圖。
研發費用增加
不斷增加的研發(R&D)費用是臨床試驗影像市場成長的主要動力。隨著製藥和生物技術公司增加研發投資以尋找新藥和治療方法,需要一個有效的臨床試驗系統。隨著這些公司在研發上投入更多資金,對臨床試驗影像服務的需求也隨之增加,因為影像對於確定新藥的有效性和安全性至關重要。 Qureight Ltd. 宣布完成價值 850 萬美元的 A 輪融資,透過臨床試驗成像推進新藥開發的成像。 Qureight Ltd. 的數位基礎設施公司管理各種醫療數據以進行全面測試。 Qureight Ltd. 透過與英國 NHS 簽訂的數據協議擁有獨特的醫療保健訪問權限,使我們能夠直接從醫院和臨床研究組織 (CRO) 即時收集 CT 掃描、生物標誌物和其他臨床試驗終點。
醫療影像公司的擴張推動市場成長
由於對改善診斷能力和技術進步的需求不斷增加,醫學影像公司持續成長。一個顯著的發展是便攜式手持成像技術的生產,例如袖珍超音波機,可以在各種模式和成像位置提供護理點診斷。此外,將人工智慧和機器學習融入診斷成像系統可以提高診斷準確性和工作流程效率。西門子 Healthineers 和 GE Healthcare 等公司正在推出便攜式 MRI 系統和自動 X 光掃描儀等突破性技術,以提高可及性並加快操作速度。 2023 年 12 月,GE Healthcare Technologies Inc. 在美國放射學會科學會議和年會 (RSNA 2023) 上宣布推出一款基於人工智慧的新型 MRI 機器。
本報告提供全球臨床試驗成像市場相關調查分析,提供市場規模與預測,市場動態,主要企業的形勢及預測等資訊。
Global clinical trial imaging market is projected to witness a CAGR of 8.01% during the forecast period 2024-2031, growing from USD 1.35 billion in 2023 to USD 2.50 billion in 2031. The global clinical trial imaging market is being driven by factors such as growing expenditures in research and development, expansion of medical imaging companies, and increasing number of Clinical Research Organizations (CROs).
Medical imaging is essential for the development of advanced life science devices and kits. Despite the ever-changing nature of the medical imaging market, the biotechnology and pharmaceutical industries are experiencing consistent growth. This is mostly owing to increased investment in medical imaging firms, and mergers and acquisitions including the adoption of innovative imaging technology to facilitate clinical trials for medical devices. Technological advancements are significantly improving the collection, interpretation, and submission of clinical trial imaging data. Technology-based imaging, particularly image analysis software, brings several advantages to clinical research, including uniformity, data quality, flexibility, and compliance. For instance, image analysis software may be used to guide and supervise a reader by evaluating imaging points in time. Furthermore, the increasing use of imaging technologies, along with improved processing power, is projected to accelerate the use of imaging in clinical trials. The Quantitative Imaging Biomarkers Alliance (QIBA) program has developed standardized methodologies and imaging processes to achieve scientifically and precisely defined outcomes in clinical studies.
In May 2024, Parexel International Corporation (Calyx Medical Imaging) announced its involvement in the pivotal phase II clinical study of Iovance Biotherapeutic's Amtagvi (lifileucel), a cell therapy for people with metastatic melanoma who have failed existing front-line treatments. Calyx helped develop and implement the imaging components of trials. Thus, 60 investigation sites were able to collect patient CT, magnetic resonance imaging (MRI), positron emission tomography (PET), and skin photography pictures in accordance with the image review methodology.
Growing Expenditures in Research and Development
Rising research and development (R&D) expenditures are a major driver for the growth of the clinical trial imaging market. Pharmaceutical and biotechnology businesses are growing their investment in R&D in search of new drugs and cures, necessitating effective clinical trial systems. As these corporations devote more money to R&D, the need for clinical trial imaging services increases, as imaging is critical in determining the efficacy and safety of new medicines. Qureight Ltd. announced their Series A round completion worth USD 8.5 million for expediting drug development imaging through clinical trial imaging. Qureight Ltd.'s digital infrastructure houses curates a variety of medical data for thorough examination. Qureight Ltd. has unique healthcare access through NHS England data contracts, allowing it to collect CT scans, biomarkers, and other trial endpoints directly from hospitals or clinical research organizations (CROs) in real time.
Expansion of Medical Imaging Companies to Drive Market Growth
Medical imaging firms are growing due to increased demand for enhanced diagnostic capabilities and technical advancements. Notable developments include manufacturing of portable and handheld imaging technologies, such as pocket-sized ultrasound devices, which provide point-of-care diagnostics in different modalities and imaging positions. Additionally, incorporating artificial intelligence (AI) and machine learning into imaging systems improves diagnosis accuracy and workflow efficiency. Companies such as Siemens Healthineers and GE Healthcare are introducing revolutionary technologies such as portable MRI systems and automated x-ray scanners to increase accessibility and accelerate operations. In December 2023, GE Healthcare Technologies Inc. announced the launch of its new AI-based MRI machine at the Radiological Society of America Scientific Sessions and Annual Meetings (RSNA 2023).
CT Scans Dominate the Global Clinical Trial Imaging Market Share
Computed tomography (CT) devices have been frequently used in clinical trial imaging due to their ability to produce detailed images of internal organs. CT scans use X-rays and computer processing to generate comprehensive cross-sectional digital images of the body, allowing clinicians and researchers to detect and quantify changes in tissues and organs over time. CT scans are secure and convenient for patients and researchers. Furthermore, researchers prefer CT scans as they can generate large volumes of data in a short period of time, which is useful for collecting and analyzing data from several patients to detect trends and patterns. The fast-track coronary artery bypass grafting (CABG) study, was led by the University's CORRIB research center for advanced imaging and core lab. Heart surgeons planned and performed CABG using non-invasive cardiac-CT scan images with the help of HeartFlow's AI-powered blood flow analysis, the doctors were able to identify problems in patient's coronary arteries.
Oncology to Account Dominant Market Share
Oncology is the leading segment amongst different types of therapeutic areas. The factors such as high prevalence of cancer cases and constant need for new and innovative therapies to treat various cancer types are expected to fuel market growth. Oncology trials often involve complex imaging requirements due to the need to assess tumor size, treatment responses, and disease progression. Various imaging modalities, such as CT scans, MRI, PET scans, and others, are used to evaluate the effectiveness of cancer treatments. This complexity results in a larger share of the market being dedicated to oncology.
Future Market Scenario (2024-2031F)
Future clinical trials will be increasingly employed with multi-modal imaging techniques, combining various imaging modalities such as MRI, CT, and PET. This approach will offer a comprehensive view of anatomical and physiological processes, facilitating better correlation of findings and improving the overall understanding of pathologies.
The use of wearable devices will provide continuous, real-time health data from trial participants. The technology aims to enhance patient engagement and reduce the burden of participation by allowing remote monitoring, thus making clinical trials more accessible and patient centric.
AI is set to revolutionize clinical trial imaging by enhancing diagnostic accuracy and efficiency. AI algorithms will improve image quality, reduce scan times, and automate tasks such as image interpretation and report generation. It will allow radiologists to focus on more complex cases while ensuring timely and precise disease detection.
The trend towards decentralized clinical trials will continue, leveraging technology to conduct trials remotely. It will involve partnerships with end-to-end solution providers who can manage imaging logistics, data harmonization, and secure analysis, ultimately enhancing trial efficiency and participant experience.
Key Players Landscape and Outlook
Several medical imaging companies and clinical research organizations are growing in the global clinical trial imaging market by planning and adopting new strategies. New agreements, contracts, mergers and acquisitions, investments, and partnerships, along with major strategic initiatives through which companies are increasing their market shares.
Pie Medical Imaging Inc., a global leader in cardiac imaging, announced in June 2024 its enrollment in FASTIII, a multi-center randomized clinical trial. The trial is investigating the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. The vFFR can determine whether a coronary artery narrowing is functionally substantial and requires revascularization.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.